Australis Partners led an equity investment into Sekura, its Mexican insurance brokerage platform, to partially finance the acquisition of Alternativas en Riesgos (AER), the leading northern Mexico insurance broker based in Monterrey. The resulting combination gives shape to the largest independent corporate insurance broker in Mexico, with over 500 employees across the country, operating in the four largest and most important markets in Mexico including Mexico City, and with a combined 8.0 billion pesos in premiums placed in health, P&C, life, auto, and sureties for 2022.
The acquisition was financed by an […]
Australis Partners Fund L.P. (“Australis Partners”) announced that it has completed the divestiture of all its ownership stakes in portfolio companies Disal Ambiental Holding (“DAH”) and Inversiones Disal Emergencias S.A. (“IDE”, and together with DAH “Disal”), through a cash sale to Ambipar Participacoes e Empreendimentos S.A. (“Ambipar”).
DAH is the Chilean holding of companies with 40 years of expertise providing comprehensive waste management solutions, portable toilets, and management of water treatment plants to industrial clients in Chile, Peru and Paraguay through a network of 45 branches. IDE owns a 50% stake in Suatrans Chile,which has been […]
SEKURA CONTROLADORA S.A.P.I. DE C.V. (“Sekura”) today announced that it has entered into a definitive agreement with Australis Partners, an independent private equity firm focused on Latin America, under which Australis Partners acquired a majority stake in the company. Founded in 1951, Sekura is a rapidly growing multiline insurance, surety and affinity brokerage firm serving more than 550 corporate clients throughout Mexico. As part of this transaction, Arpa Capital and non-executive shareholders exited from the ownership of Sekura.
“This alliance with Australis Partners is a landmark in Sekura’s history. It’s the next step […]
Santiago, December 29, 2020 – Australis Partners Fund L.P. (“Australis Partners”) has completed the acquisition of 80% of the shares of Galénica S.A. (“Galénica” or the “Company”). Financial terms of the transaction were not disclosed.
The Company is a leading in vitro diagnostics player in Chile, focused on the import, distribution, commercialization and post-sale services of medical equipment and reagents through its global brand partnerships. The Company has more than 30 years of presence in the Chilean Health System and multinational distribution partnerships related to medical equipment and supplies for clinical diagnosis, blood bank, molecular […]